Results for this period
Interim period (second quarter)1 March 2026 to 31 August 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.
The shaded area represents net assets as a proportion of total assets. It is calculated from the two amounts reported by the company.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Revenue increased as orders for pharmaceuticals and cosmetics at the French consolidated subsidiary remained firm, and as a result of the weaker yen. On the profit front, inflation-driven increases in raw material costs, personnel expenses and various other expenses, as well as delays in passing costs on to prices, put pressure on profit.
No applicable matters.
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 March 2026 to 31 August 2026 |
| Net Sales | ¥9,155 million (YoY +14.0%) |
| Operating profit | ¥50 million (YoY -54.4%) |
| Ordinary income | ¥-14 million |
| Profit attributable to owners of the parent | ¥-21 million |
| Total assets | ¥17,898 million |
| Net assets | ¥4,179 million |
| Cash flows from operating activities | ¥260 million |
| Cash flows from investing activities | ¥-963 million |
| Cash flows from financing activities | ¥466 million |
| Cash and cash equivalents at end of period | ¥846 million |
| Revision to Earnings Forecast | No change |
| Segment revenue | Japan ¥6,129,348 thousand (YoY +6.7%), France ¥3,147,318 thousand (YoY +34.6%) |
| Segment profit | Japan ¥55,740 thousand (YoY -71.1%), France ¥194 thousand |
| Regional sales | ¥6,129,348 thousand (YoY +6.7%), ¥3,147,318 thousand (YoY +34.6%) |
| Depreciation and amortization | ¥474,543 thousand |
| Impairment loss | No applicable matters. |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥2,045 thousand / Extraordinary loss Loss on Disposal of Fixed Assets ¥532 thousand |
| Disclosure regarding the going concern assumption | No applicable matters. |
| Factors Behind Changes in Business Performance | Revenue increased as orders for pharmaceuticals and cosmetics at the French consolidated subsidiary remained firm, and as a result of the weaker yen. On the profit front, inflation-driven increases in raw material costs, personnel expenses and various other expenses, as well as delays in passing costs on to prices, put pressure on profit. |
Items this document does not state (15)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.As domestic orders slowed recently, inflation drove up raw material costs, including those for crude oil-derived products, as well as personnel expenses and various other expenses, while the pass-through of higher costs to prices also failed to make sufficient progress. On the other hand, the recovery in orders for pharmaceuticals and cosmetics at the French consolidated subsidiary, together with the weaker yen, boosted revenue.